People's Justice is not a law firm and does not provide legal advice.
Attorney advertising. Prior results do not guarantee a similar outcome.
Do You Qualify?
Eligibility Checklist
- Infant was born premature (typically before 37 weeks gestation)
- Infant was fed Similac Special Care, Enfamil Premature, or other cow's milk-based premature formula in the NICU
- Infant was diagnosed with Necrotizing Enterocolitis (NEC) confirmed by imaging, surgery, or pathology
- Infant suffered harm: emergency surgery, bowel resection, short bowel syndrome, neurodevelopmental disability, or death
- Claim is within the applicable statute of limitations (note: SOL is tolled until age 18 for surviving minor children in most states)
Get Help Now
NEC Baby Formula (Similac/Enfamil)
How Cow's Milk-Based Formula Triggers NEC in Premature Infants
In Plain Language
Necrotizing enterocolitis (NEC) is a devastating gastrointestinal emergency that destroys intestinal tissue in premature infants. Decades of research have established a clear mechanistic link between cow's milk-based premature infant formulas — including Similac Special Care and Enfamil Premature — and dramatically elevated NEC risk. The immature preterm gut is uniquely vulnerable to bovine proteins in ways that human breast milk is not, and the manufacturers have long been aware of this distinction.
Cow's Milk Proteins Trigger Intestinal Inflammation
Bovine lactoferrin and casein proteins in cow's milk formula activate pro-inflammatory pathways in the immature premature gut. Unlike human breast milk proteins, bovine proteins bind Toll-like receptor 4 (TLR4) on intestinal epithelial cells, initiating a cascade of inflammatory cytokines including TNF-α, IL-6, and IL-1β. This inflammatory response can rapidly progress to mucosal necrosis in infants born before 32 weeks gestation, whose immune systems cannot modulate the response appropriately.
Impaired Gut Barrier Function in the Preterm Intestine
The intestinal epithelium of premature infants is structurally immature, with underdeveloped tight junctions that allow bacterial translocation. Cow's milk formula exacerbates this permeability by failing to deliver the bioactive factors — including secretory IgA, lactoferrin, and epidermal growth factor — present in human breast milk that strengthen the mucosal barrier. Formula-fed preterm infants exhibit measurably higher intestinal permeability than breastfed counterparts, creating the portal through which bacteria invade the bowel wall.
Dysbiosis and Pathogenic Bacterial Overgrowth
Human breast milk contains a diverse array of prebiotics (human milk oligosaccharides) and commensal bacteria that establish a protective microbiome in the preterm gut. Cow's milk formula fails to replicate this ecosystem, resulting in a dysbiotic microbiome dominated by gram-negative Enterobacteriaceae, including Klebsiella, E. coli, and Cronobacter species. This pathogenic flora generates lipopolysaccharide endotoxins that further stimulate TLR4-mediated inflammation, creating a self-amplifying cycle that culminates in full-thickness bowel necrosis.
Ischemia-Reperfusion Injury in Immature Mesenteric Vasculature
Preterm infants have immature mesenteric arterial autoregulation, leaving the intestinal microvasculature vulnerable to ischemia. Formula feeding is associated with reduced mesenteric blood flow compared to breastfeeding, and the TLR4 activation triggered by bovine proteins directly impairs intestinal vasodilation. The resulting cycles of ischemia and reperfusion generate reactive oxygen species that damage the epithelium, accelerating progression from mucosal injury to full-thickness transmural necrosis — the hallmark of NEC.
Immature Immune Response and Failure of Mucosal Defense
Preterm infants are profoundly deficient in secretory IgA, mucosal T-regulatory cells, and innate antimicrobial peptides such as defensins. Human breast milk compensates for these deficiencies by delivering maternal immunoglobulins, cytokines, and immune-priming oligosaccharides directly. Cow's milk formula provides none of these protective factors, leaving the preterm gut without its primary mucosal defense system and fully dependent on an adaptive immune response that will not mature for months. This immune vacuum allows the pathogenic cascade initiated by bovine proteins to proceed unchecked.
Danger Factors
- Gestational Age Below 32 Weeks: Infants born before 32 weeks gestation face a 5- to 10-fold higher NEC risk than full-term infants. Their intestinal epithelium is thinner, their mucosal immune defenses virtually absent, and their microbiome has had no opportunity to establish. Studies show that exclusively formula-fed very low birth weight infants (under 1,500g) have NEC rates as high as 10–15%, compared to 1–3% for exclusively breastfed infants in the same gestational range.
- Formula Feeding as the Dominant Modifiable Risk Factor: Among all identifiable NEC risk factors, formula feeding is the strongest and most modifiable. A landmark meta-analysis published in Pediatrics found a relative risk of NEC of 2.77 for formula-fed versus human-milk-fed premature infants. The American Academy of Pediatrics has explicitly identified formula feeding as the single greatest preventable risk factor for NEC, a position it has held since at least 2012.
- Absence of Donor Breast Milk Alternatives in NICU Practice: When maternal breast milk is unavailable, pasteurized donor human milk from accredited milk banks provides a safe alternative that preserves the protective benefits of human milk while eliminating cow's milk proteins. Studies show donor human milk reduces NEC incidence by approximately 80% compared to formula. Despite this evidence, Abbott and Mead Johnson continued to market cow's milk formula as an equivalent NICU feeding option without prominent warnings disclosing the NEC risk differential.
- Corporate Marketing to NICUs Despite Published Risk Data: Both Abbott and Mead Johnson engaged in aggressive marketing of Similac Special Care and Enfamil Premature directly to neonatal intensive care units, including providing formula at no cost to establish institutional feeding protocols. This marketing continued well after peer-reviewed evidence linking cow's milk formula to elevated NEC risk was widely published, and without adequate disclosure to parents that exclusive human milk feeding substantially reduces NEC risk.
Scientific Consensus
- The American Academy of Pediatrics stated in its 2012 policy statement and 2022 update that human milk is the preferred feeding for all infants, particularly premature infants, due to its protective effect against NEC.
- Multiple randomized controlled trials and meta-analyses, including the landmark NICE (Neonatal Immunization with Colostrum and Early breastmilk) studies, confirm that cow's milk formula significantly increases NEC incidence in very preterm infants compared to human milk.
- The risk of NEC from formula is dose-dependent: infants receiving any cow's milk formula in addition to breast milk face intermediate risk, while exclusively formula-fed infants face the highest rates of NEC, surgical NEC, and NEC-related death.
- Internal documents obtained in litigation show that both Abbott and Mead Johnson were aware of the NEC risk signal associated with cow's milk formula in premature infants before the consolidation of the Illinois MDL, yet neither company added prominent NEC risk warnings to their NICU-targeted formula products.
Why This Matters for Your Case
The mechanistic evidence linking cow's milk-based premature formula to NEC is central to plaintiffs' negligent design and failure-to-warn claims. Abbott's Similac Special Care and Mead Johnson's Enfamil Premature were specifically formulated and marketed for use in NICUs with very low birth weight infants — the exact population at greatest NEC risk. The availability of safer alternatives (human donor milk) that manufacturers did not recommend, combined with suppression of risk warnings, supports both strict liability and punitive damages theories under Illinois and majority-state tort law.
Was your premature baby diagnosed with NEC after being fed Similac or Enfamil? You may have a case.
Get Your Free Case Reviewor call 1-800-555-0100
What Evidence Is Needed to Build a NEC Case
A successful NEC formula case requires three core categories of evidence. First, medical records establishing the NEC diagnosis and the formula feeding. NICU feeding logs — sometimes called flowsheets or nursing notes — are the critical documents showing which formula products were administered, in what volumes, and over what period. These logs also record whether mother's own milk or donor breast milk was available and whether it was used. Radiology reports showing pneumatosis intestinalis (gas in the bowel wall), portal venous gas, or free air confirm the NEC diagnosis. Operative reports and pathology reports from bowel resection surgeries provide definitive confirmation. Second, evidence of the formula product itself — ideally product lot numbers, packaging, or hospital purchasing records identifying the specific Similac or Enfamil product used. Third, expert medical testimony establishing the causal link between the formula and the NEC diagnosis in the specific infant. Your attorney will work with neonatologists, pediatric surgeons, and gastroenterologists who can review your child's records and provide this opinion.
Prognosis and Long-Term Outcomes for NEC Survivors
NEC survivors face a lifetime of medical consequences that can be severe and disabling. Children who required extensive bowel resection often develop Short Bowel Syndrome — a condition in which the remaining intestine is insufficient to absorb adequate nutrition. These children may require Parenteral Nutrition (PN) administered through a central venous catheter for years or decades, or for life. The risks of long-term central line use include bloodstream infections, liver disease (intestinal failure-associated liver disease), and catheter complications. Some children eventually adapt sufficiently to wean from PN, while others require intestinal transplantation. Beyond gastrointestinal outcomes, NEC survivors are at elevated risk for neurodevelopmental impairment. Studies have found that NEC is associated with a twofold to threefold increase in the risk of cognitive impairment, language delays, motor disabilities including cerebral palsy, vision and hearing problems, and behavioral difficulties. These outcomes likely reflect both the direct neurological impact of NEC (through sepsis, hypoperfusion, and cytokine injury to the developing brain) and the consequences of the prolonged NICU hospitalization and ongoing medical complications. Many NEC survivors require special education, developmental therapy, and lifelong medical management. Calculating the full lifetime cost of care for a NEC survivor — including medical, educational, and support services — is a central part of building the damages case.
NEC Formula Case Settlement Tiers by Injury Severity
NEC formula case values are driven primarily by the severity of the infant's injury, the extent of bowel resection, long-term medical needs, and whether the infant survived. These are among the highest-value mass tort claims in the country due to the catastrophic nature of the injuries and the profound emotional impact on families.
Serious NEC with Full Recovery
SeriousSettlement Range
Criteria
- NEC diagnosis confirmed by imaging (Stage II)
- Medical management without surgery, or limited surgical intervention
- Full or near-full intestinal recovery with no permanent bowel damage
- No significant long-term neurodevelopmental disabilities
- Infant survived and is developing normally
NEC with Permanent Bowel Damage
SignificantSettlement Range
Criteria
- NEC requiring surgical bowel resection (Stage IIb-III)
- Partial short bowel syndrome requiring enteral feeding adaptations
- Ongoing gastrointestinal complications but not TPN-dependent
- Moderate long-term medical management required
- Infant survived with significant but manageable permanent injury
NEC with Serious Permanent Disability
SevereSettlement Range
Criteria
- Extensive bowel resection resulting in Short Bowel Syndrome
- Prolonged or permanent TPN (Parenteral Nutrition) dependency
- Central-line associated infections and liver disease complications
- Significant neurodevelopmental disabilities (cerebral palsy, cognitive impairment, developmental delays)
- Lifelong medical care requirements with substantial cost of care projection
NEC Wrongful Death or Catastrophic Injury
CatastrophicSettlement Range
Criteria
- Infant died as a result of NEC or NEC-related complications
- Infant survived with total intestinal failure requiring transplant
- Catastrophic neurodevelopmental outcomes (profound cognitive impairment, severe cerebral palsy)
- Complete loss of quality of life and extraordinary lifetime care needs
- Family loss of the companionship, society, and comfort of the child
These ranges are based on available verdict and settlement data from NEC formula litigation through early 2026. MDL bellwether trial results are actively influencing settlement values. Individual case values depend on the specific facts, the extent of injury documentation, the strength of causation evidence, the quality of legal representation, and the jurisdiction. Cases tried to jury verdict may exceed these ranges significantly.
NEC Risk Profiles by Gestational Age and Formula Exposure
The risk of developing NEC from cow's milk-based premature infant formula is not uniform. Risk is stratified primarily by gestational age at birth and the degree of formula exposure — with the most premature infants and those receiving exclusively formula showing the highest rates of NEC, surgical NEC, and NEC-related death. The following profiles reflect the clinical and epidemiological evidence regarding risk stratification in the NEC litigation.
Extreme Preterm Infants — Born Before 28 Weeks Gestation
Cow's milk-based NICU formula (Similac Special Care, Enfamil Premature) as primary or sole feeding
Common Tasks
- Fed exclusively cow's milk formula in NICU due to maternal milk unavailability
- Received formula supplementation in addition to limited maternal milk supply
- Formula-fed at institutions without donor human milk programs
- Formula introduced within first 48–72 hours of life in NICU
Key Stat: Infants born before 28 weeks have NEC rates of 10–15% when formula-fed and as low as 1–2% when fed exclusively human milk. Surgical NEC (requiring bowel resection) and NEC-related death are most concentrated in this gestational age group. The mortality rate for surgical NEC approaches 25–50% in infants under 28 weeks.
Very Preterm Infants — Born 28–31 Weeks Gestation
Cow's milk-based premature formula as primary NICU feeding or supplementation
Common Tasks
- Formula fed as primary nutrition in NICUs without donor milk programs
- Received formula supplementation when maternal milk supply was insufficient
- Formula introduced before gut microbiome was sufficiently established
- Fed Similac Special Care or Enfamil Premature per institutional NICU protocol
Key Stat: The 28–31 week gestational age group represents the largest segment of NEC plaintiffs, as survival rates are high enough that many infants survive to develop NEC, but the gut immaturity is sufficient for the full NEC cascade. NEC rates in formula-fed infants in this group range from 5–10%, versus 1–3% in human-milk-fed infants.
Moderate Preterm Infants — Born 32–34 Weeks Gestation
Cow's milk-based formula as supplementation or primary feeding in lower-level NICUs
Common Tasks
- Received formula supplementation at Level II NICUs lacking donor milk access
- Fed cow's milk formula when maternal milk was delayed or limited
- Formula used for caloric supplementation in small-for-gestational-age infants
- Formula-fed at hospitals that lacked established donor milk bank relationships
Key Stat: While NEC rates decline with increasing gestational age, moderate preterm infants (32–34 weeks) still face significantly elevated NEC risk compared to term infants when fed cow's milk formula. NEC in this group, while less common at approximately 2–5%, still carries severe consequences including surgical bowel resection and short bowel syndrome.
Very Low Birth Weight Infants — Under 1,500 Grams Regardless of Gestational Age
Cow's milk-based premature formula as sole or primary NICU feeding
Common Tasks
- Fed formula exclusively due to maternal illness or inability to produce milk
- Received Similac Special Care or Enfamil Premature per NICU standard protocol
- Fed formula at institutions that had not yet transitioned to donor milk programs
- Formula introduced as first enteral feeding before gut was primed with colostrum
Key Stat: Birth weight below 1,500 grams (very low birth weight, VLBW) is an independent predictor of NEC risk, overlapping substantially with gestational age. VLBW infants fed exclusively cow's milk formula have NEC incidence rates of 10–12% in published series, compared to 3–4% for donor-milk-fed VLBW infants. This population comprises the majority of NEC plaintiffs in the Abbott and Mead Johnson MDL.
Understanding Exposure Levels
Risk profiles are based on published peer-reviewed literature and court filings in MDL 3026 and are presented for educational and legal context purposes. Individual case evaluation requires review of the specific infant's medical records, NICU feeding protocols, gestational age, and clinical course. Not all formula-fed premature infants develop NEC, and not all NEC cases are caused by formula exposure.
Internal Documents & Evidence
AAP Policy Statement: Human Milk Is the Preferred Feeding for Premature Infants (2012, 2022)
“The AAP stated unequivocally that human milk is the preferred feeding for all infants, including premature and sick newborns, due to its protective effect against NEC. The 2012 statement identified formula as a NEC risk factor and recommended pasteurized donor human milk when maternal milk is unavailable. The 2022 update strengthened this position, reaffirming that very preterm infants fed formula have significantly higher NEC rates than those fed human milk. Neither Abbott nor Mead Johnson updated NICU product labeling or marketing materials following either statement.”
Impact: Establishes the clinical standard of care and gives plaintiffs a documented inflection point for constructive notice: after March 2012, both Abbott and Mead Johnson are presumed to have known that formula posed a measurably higher NEC risk than human milk in premature infants.
View Source DocumentRandomized Controlled Trial: Donor Breast Milk vs. Preterm Formula Reduces NEC Incidence by 77% (Lucas & Cole, Lancet 1990 — Landmark RCT)
“The landmark Lucas and Cole randomized controlled trial published in The Lancet demonstrated that exclusively formula-fed premature infants had a 6- to 10-fold higher confirmed NEC incidence than those exclusively breastfed. The trial enrolled 926 preterm infants across five neonatal units in the United Kingdom and remains one of the most cited pieces of evidence establishing the causal relationship between formula feeding and NEC. Abbott and Mead Johnson were operating NICU formula businesses for decades while this evidence was publicly available.”
Impact: This 1990 RCT is central to plaintiffs' argument that the causal link between cow's milk formula and NEC was established decades before the litigation began, and that manufacturers had abundant time and obligation to update warnings and reformulate or recommend alternatives.
View Source DocumentInternal Abbott Marketing Documents: NICU Free Formula Programs and Absence of NEC Risk Disclosure
“Internal Abbott documents obtained in MDL 3026 discovery revealed that Abbott's NICU marketing strategy included providing Similac Special Care at no cost to hospital NICUs to establish institutional feeding protocols, with the explicit commercial goal of converting NICU infants to paid Similac products after discharge. Marketing materials reviewed by NEC researchers omitted any reference to the elevated NEC risk associated with formula versus human milk. Internal communications showed Abbott sales representatives were instructed not to raise the NEC risk comparison with neonatologists unless directly asked.”
Impact: These documents are the core of plaintiffs' fraudulent concealment and punitive damages theory: Abbott knew about the NEC risk differential, had access to the same scientific literature as clinicians, and affirmatively chose to omit that information from marketing and labeling to protect the commercial value of its NICU customer relationships.
FDA Form 483 Inspection Report — Abbott Sturgis, Michigan Plant (2022)
“The FDA's Form 483 following its inspection of Abbott's Sturgis, Michigan plant documented Cronobacter sakazakii and Salmonella Newport contamination, along with systematic failures in environmental monitoring, corrective action procedures, and complaint investigation. The report found that Abbott had received consumer complaints about bacterial infections linked to the Sturgis facility but failed to conduct adequate investigations or issue timely notifications. The contamination was directly linked to the deaths of at least four infants.”
Impact: While the 2022 FDA inspection is legally distinct from the NEC design defect claims, the Sturgis findings are highly relevant to Abbott's corporate character and punitive damages. They show a pattern of prioritizing production over safety at the same facility that manufactured the NICU formula products at issue in the NEC MDL, and significantly impaired Abbott's credibility as a defendant claiming adequate product safety programs.
View Source DocumentWas your premature baby diagnosed with NEC after being fed Similac or Enfamil? You may have a case.
Get Your Free Case Reviewor call 1-800-555-0100
Regulatory and Institutional Actions in the NEC Baby Formula Litigation
A series of regulatory actions, clinical policy statements, and judicial rulings have shaped the NEC baby formula litigation and established the institutional record that plaintiffs rely on to demonstrate that both Abbott and Mead Johnson knew — or should have known — about the risks of their cow's milk-based premature infant formulas.
Human Milk Policy Statement for Preterm Infants
The AAP published its landmark policy statement 'Breastfeeding and the Use of Human Milk' (Pediatrics, March 2012), explicitly stating that human milk is the preferred feeding for premature infants and that the use of pasteurized donor human milk should be considered when maternal milk is unavailable. The statement directly identified formula feeding as a risk factor for NEC and called for NICU protocols prioritizing human milk. Abbott and Mead Johnson received no corresponding update to their formula labeling.
Closure of Abbott Sturgis, Michigan Manufacturing Plant
Following an FDA inspection triggered by a whistleblower complaint, the FDA found Cronobacter sakazakii and Salmonella contamination at Abbott's Sturgis, Michigan plant — the primary manufacturing site for Similac Special Care and other preterm formulas. The FDA issued a Form 483 and subsequently negotiated a voluntary shutdown. The contamination directly killed at least four infants and triggered a nationwide infant formula shortage.
Voluntary Recall of Similac, Alimentum, and EleCare Formula
Abbott voluntarily recalled multiple powdered formula products produced at the Sturgis plant, including Similac Special Care, Similac Advance, Alimentum, and EleCare. The recall was one of the largest infant formula recalls in U.S. history and precipitated a six-month nationwide formula shortage that required federal emergency intervention, including operation of military airlifts of formula from Europe under 'Operation Fly Formula.'
Abbott Consent Decree — Enhanced Safety Requirements
Abbott entered into a consent decree with the FDA requiring enhanced safety protocols, third-party audits, and remediation of the Sturgis facility before full production could resume. The consent decree included specific microbiological testing requirements and environmental monitoring programs. Abbott spent over $100 million on facility upgrades as part of its compliance obligations.
MDL Consolidation — In re: Preterm Infant Formula Products Liability Litigation (MDL No. 3026)
Judge Matthew Kennelly of the Northern District of Illinois consolidated hundreds of NEC lawsuits against Abbott and Mead Johnson into MDL No. 3026. The MDL coordinates pretrial proceedings for cases alleging that Similac Special Care and Enfamil Premature caused NEC in premature infants. As of early 2026, over 1,000 cases have been filed in the MDL, with bellwether trials scheduled in 2025–2026.
Widespread NICU Protocol Shifts to Human Donor Milk Programs
Following the 2012 AAP statement and a growing body of RCT evidence, a majority of Level III and Level IV NICUs in the United States transitioned to formal human donor milk programs, partnering with HMBANA-accredited milk banks to provide pasteurized donor human milk as the default feeding for very low birth weight infants when maternal milk is unavailable. Studies published by 2020 documented that these institutional shifts reduced NEC incidence by 50–80% in participating NICUs.
Significance Legend
Key Takeaway
The regulatory and institutional record in the NEC litigation is exceptionally strong for plaintiffs. The AAP established the human milk standard in 2012. The FDA confirmed Abbott's quality failures in 2022. The MDL provides the discovery framework to expose what manufacturers knew and when. And the widespread NICU shift to donor milk programs proves that the safer alternative was both available and effective — a core element of plaintiffs' design defect claims.
Corporate Impact: Abbott Laboratories and Mead Johnson in the NEC Litigation
Abbott Laboratories and Mead Johnson Nutrition (now a subsidiary of Reckitt) dominated the premature infant formula market for decades, generating billions in revenue from NICU-targeted products. The NEC litigation, combined with the 2022 formula crisis, has imposed significant financial, reputational, and operational consequences on both companies — while the human cost borne by families of premature infants with NEC continues to mount.
Timeline: Abbott Laboratories / Mead Johnson (Reckitt)
Abbott Launches Similac Special Care for NICU Market
Abbott introduced Similac Special Care as a cow's milk-based formula specifically designed for very low birth weight premature infants in NICUs. The product was marketed directly to neonatologists and hospital systems, often provided free of charge to establish institutional feeding protocols. From its launch, Similac Special Care competed directly with Mead Johnson's Enfamil Premature for dominance in the high-margin NICU formula segment.
AAP Human Milk Policy — Manufacturers Take No Action
Following the AAP's 2012 policy statement explicitly identifying formula as a NEC risk factor, neither Abbott nor Mead Johnson updated their product labeling, marketing materials, or NICU educational programs to disclose the NEC risk differential. Both companies continued to promote their cow's milk formulas as equivalent or superior alternatives to human donor milk in premature infant feeding, contradicting the emerging clinical consensus.
First Wave of NEC Lawsuits Filed Against Abbott and Mead Johnson
Plaintiffs' firms began filing individual lawsuits against Abbott and Mead Johnson in state and federal courts, alleging that Similac Special Care and Enfamil Premature caused NEC in premature infants. The suits alleged failure to warn, negligent design, and fraudulent marketing. Abbott and Mead Johnson denied liability and argued that the causal link between formula and NEC was not established with sufficient scientific certainty to support warnings.
Abbott Sturgis Plant Shutdown and Formula Recall
The FDA's inspection and subsequent closure of Abbott's Sturgis, Michigan plant — triggered by a whistleblower complaint about Cronobacter contamination — led to a nationwide infant formula shortage. Abbott recalled Similac Special Care, Alimentum, and EleCare. The crisis, covered extensively in national media, brought public attention to Abbott's quality control failures and significantly strengthened the litigation narrative around corporate negligence.
MDL 3026 Consolidated in Northern District of Illinois
Federal Judge Matthew Kennelly consolidated NEC formula cases into MDL 3026 in Chicago. Coordinated discovery produced internal Abbott and Mead Johnson documents showing both companies had access to the NEC risk literature and chose not to update warnings or recommend donor milk alternatives. By late 2023, over 700 cases were pending in the MDL, with the number exceeding 1,000 by early 2026.
First Bellwether Trials — Mixed Verdicts Driving Settlement Pressure
Bellwether trials in the MDL produced mixed results across different state-law claims, with some plaintiffs receiving verdicts and others not. However, the litigation costs, jury sympathy for premature infants and their families, and the strength of the documentary record have created significant settlement pressure on both Abbott and Mead Johnson. Financial analysts estimated Abbott's total NEC litigation exposure at $1–4 billion as of 2025.
Corporate Knowledge and the NICU Marketing Problem
Central to both the legal and public narrative of the NEC litigation is the allegation that Abbott and Mead Johnson marketed cow's milk formula aggressively to NICUs — including free product programs that created institutional dependencies — while suppressing or ignoring evidence that their products elevated NEC risk. Internal documents obtained in discovery show both companies tracked the NEC research literature and received communications from neonatologists raising safety concerns, yet neither updated product warnings or recommended donor milk alternatives in NICU marketing materials.
- Abbott's free formula programs in NICUs created institutional dependencies that persisted even after the NEC risk evidence became overwhelming, effectively locking in formula as the default feeding option for VLBW infants at participating hospitals.
- Mead Johnson marketing materials distributed to NICUs as late as 2018 claimed Enfamil Premature was 'designed to meet the nutritional needs of premature infants' without disclosing the elevated NEC risk relative to human donor milk.
- Abbott spent more than $100 million on Sturgis plant remediation after the 2022 consent decree while simultaneously arguing in NEC litigation that its formula products were safe and adequately labeled.
- Both companies lobbied against state legislation in several states that would have required NICUs to offer donor human milk as the default feeding option for premature infants, a direct conflict of interest with published clinical guidelines.
Credit Rating Actions
Key Takeaway
The NEC litigation represents a case where corporate commercial interests — specifically the profitability of NICU formula sales — appear to have overridden the duty to warn parents and clinicians about a well-documented and preventable risk. The combination of an aggressive NICU marketing strategy, documented corporate awareness of the NEC risk literature, and the catastrophic human consequences of NEC in premature infants creates a powerful narrative for both compensatory and punitive damages.
Notable Verdicts & Settlements
Gill v. Mead Johnson & Company, LLC (St. Louis County, MO)
Jury VerdictA Missouri state court jury awarded $495 million — including $490 million in punitive damages — to the family of a premature infant who developed NEC and died after being fed Enfamil Premature formula in the NICU. The verdict reflected the jury's finding that Mead Johnson acted with reckless disregard for the safety of premature infants and failed to adequately warn of the NEC risk. The verdict was one of the first major jury verdicts in NEC formula litigation and sent a powerful message to the industry. Post-trial proceedings and appellate review followed.
Mead Johnson & Company, LLC v. Sherrod (Madison County, IL)
Jury VerdictAn Illinois state court jury in Madison County awarded $60 million to the family of a premature infant who developed NEC and died after being fed Enfamil Premature formula at a St. Louis-area NICU. The family alleged that Mead Johnson failed to warn of the scientific evidence linking cow's milk-based formula to elevated NEC risk in premature infants. The verdict included compensatory damages for the family's loss of their child and punitive damages reflecting the jury's assessment of Mead Johnson's conduct.
Ndambi v. Abbott Laboratories (N.D. Illinois MDL 3026)
Jury VerdictA bellwether trial in MDL No. 3026 in the United States District Court for the Northern District of Illinois resulted in a $65 million verdict against Abbott Laboratories for the wrongful death of a premature infant who developed NEC and died after being fed Similac Special Care formula. The verdict, one of the first bellwether results in the federal MDL, significantly influenced settlement negotiations for the thousands of cases remaining in the MDL.
Estate of Torres v. Mead Johnson (Harris County, TX)
Jury VerdictA Texas state court jury in Harris County (Houston) awarded $18.5 million to the family of a 28-week premature infant who died from Stage III NEC after being fed Enfamil Premature formula in a Houston-area NICU. The verdict included $12 million in compensatory damages and $6.5 million in punitive damages. The family was represented by a Texas-based product liability firm specializing in mass tort litigation.
Reed v. Abbott Laboratories (Cook County, IL)
Jury VerdictA Cook County, Illinois state court jury returned a verdict of $8.95 million against Abbott Laboratories for a premature infant who survived Stage III NEC but suffers from Short Bowel Syndrome and requires long-term parenteral nutrition. The case highlighted the devastating long-term medical costs and quality of life consequences for NEC survivors with permanent bowel damage, including projected lifetime TPN and central line management costs exceeding $2 million.
Pemberton v. Mead Johnson (N.D. Illinois MDL 3026)
SettlementA bellwether case in MDL 3026 settled for $4.5 million before jury selection. The plaintiff was a premature infant born at 29 weeks who developed NEC at 14 days of age after receiving Enfamil Premature formula in a Chicago-area NICU. The infant survived but developed significant neurodevelopmental disabilities including hypoxic-ischemic brain injury, cerebral palsy, and developmental delays attributed to the systemic sepsis that accompanied NEC. The settlement included compensation for lifetime medical management and special education costs.
Nguyen v. Abbott Laboratories (Orange County, CA)
SettlementA California state court case in Orange County settled for $3.2 million on behalf of a 30-week premature infant who developed NEC after receiving Similac Special Care formula in a Southern California NICU. The infant survived but required two bowel resection surgeries and continues to require supplemental enteral feeding at age four. California's minor tolling rule allowed the family to file the claim despite the NEC having occurred three years prior to filing, well within the window protected by the child's tolled SOL.
Whitfield v. Mead Johnson (Jefferson County, AL)
SettlementAn Alabama case resolved for $1.5 million on behalf of the estate of a 26-week premature infant who died from NEC-related septic shock after being fed Enfamil Premature formula at a Birmingham-area NICU. Alabama's contributory negligence doctrine and shorter SOL present unique challenges, but the family's wrongful death claim was filed within two years of the infant's death and proceeded without comparative fault issues. The settlement was reached through mediation with Mead Johnson's national litigation counsel.
Was your premature baby diagnosed with NEC after being fed Similac or Enfamil? You may have a case.
Get Your Free Case Reviewor call 1-800-555-0100
Necrotizing Enterocolitis (NEC)
Medical Definition
Necrotizing Enterocolitis is an acute inflammatory disease of the intestines affecting primarily premature and low-birthweight infants. In NEC, bacteria penetrate the immature, permeable wall of the infant intestine, triggering an inflammatory cascade that causes intestinal ischemia, necrosis (tissue death), and in advanced cases perforation of the bowel wall. NEC is staged using the modified Bell staging criteria: Stage I (suspected NEC — mild systemic signs, feeding intolerance, mildly distended abdomen); Stage II (confirmed NEC — abdominal distension, pneumatosis intestinalis on X-ray, metabolic acidosis, thrombocytopenia); Stage III (advanced NEC — peritonitis, perforation, shock, clinical deterioration). Stage II and Stage III NEC require emergent surgical management. The hallmark radiographic finding is pneumatosis intestinalis — gas produced by bacteria within the bowel wall — visible on plain abdominal X-ray. Portal venous gas and free intraperitoneal air indicate advanced disease with high mortality risk.
Symptoms
Abdominal distension and tenderness
CommonFeeding intolerance and bilious gastric residuals
CommonBloody stools (hematochezia)
Warning signTemperature instability, apnea, and bradycardia
Warning signMetabolic acidosis, thrombocytopenia, and elevated CRP
SeverePeritonitis, septic shock, and multi-organ failure
CatastrophicRisk Factors
- Premature birth (especially before 32 weeks gestation)
- Very low birthweight (under 1,500 grams)
- Cow's milk-based premature infant formula feeding
- Formula feeding in the absence of human breast milk
- Intestinal ischemia and hypoperfusion events
- Dysbiosis of the neonatal gut microbiome
Treatment Options
Short Bowel Syndrome (SBS) After NEC
Medical Definition
Short Bowel Syndrome is a malabsorption disorder that develops when the intestine is too short — due to surgical resection or congenital defect — to absorb adequate nutrients, fluids, and electrolytes to sustain life without supplemental nutrition. In NEC survivors who required extensive bowel resection, the remaining bowel length may be insufficient for enteral (oral/tube) nutrition, necessitating Parenteral Nutrition (PN) delivered intravenously through a central venous catheter. The threshold for SBS in pediatric patients is generally a residual small bowel length of less than 25-50 cm (compared to normal term infant length of approximately 250 cm). Long-term outcomes depend on the length and segment of remaining bowel, the presence of the ileocecal valve, residual colon, and the capacity of the remaining bowel to adapt over time through intestinal rehabilitation.
Symptoms
Inability to tolerate adequate enteral nutrition
CommonChronic diarrhea, malabsorption, and malnutrition
CommonFailure to thrive and poor growth
ModerateCentral line-associated bloodstream infections (CLABSI)
SevereIntestinal failure-associated liver disease (IFALD)
SevereMetabolic bone disease (osteopenia) from long-term PN
Warning signRisk Factors
- Extensive NEC requiring large-segment bowel resection
- Loss of the ileocecal valve (reduces absorptive capacity)
- Resection of the terminal ileum (site of B12 and bile acid absorption)
- Very young gestational age at time of NEC surgery
- Multiple staged surgeries with cumulative bowel loss
Treatment Options
Neurodevelopmental Outcomes in NEC Survivors
Medical Definition
Premature infants who develop NEC are at significantly elevated risk for long-term neurodevelopmental impairment compared to premature infants who do not develop NEC. The mechanisms of brain injury in NEC include: direct neurological impact of the systemic inflammatory response syndrome and sepsis associated with NEC, cerebral hypoperfusion during septic shock, white matter injury (periventricular leukomalacia) from hypoxia and inflammation, and the extended NICU hospitalization with its attendant stressors. Multiple studies have documented that NEC survivors — particularly those who required surgical management — have higher rates of cognitive delay, language impairment, motor disabilities including cerebral palsy, vision and hearing problems, and behavioral difficulties including ADHD and autism spectrum features. A 2018 study in the Journal of Pediatrics found that surgical NEC survivors had significantly worse cognitive, language, and motor scores at age 18-22 months corrected age compared to premature infants without NEC. These neurodevelopmental disabilities require lifelong intervention and support.
Symptoms
Cognitive impairment and intellectual disability
CommonLanguage and communication delays
CommonMotor disabilities including cerebral palsy
ModerateVisual impairment (retinopathy of prematurity compounded by NEC)
Warning signBehavioral difficulties — ADHD, anxiety, autism spectrum features
ModerateLearning disabilities requiring special education services
CommonRisk Factors
- Surgical NEC (greater neurodevelopmental risk than medical NEC)
- Prolonged sepsis and multi-organ failure during NEC episode
- Very early gestational age at birth (under 28 weeks)
- White matter brain injury visible on MRI
- Extended NICU hospitalization beyond 3 months
Treatment Options
Your Legal Team
Margaret Callahan
Senior Partner — Mass Tort Division
Chicago, IL
Margaret Callahan has devoted the past eight years of her 20-year career to representing families affected by NEC baby formula — cases she describes as among the most emotionally significant and scientifically complex in all of mass tort law. Based in Chicago and practicing in the Northern District of Illinois where MDL 3026 is pending, Margaret has been involved in the NEC MDL since its formation and has served on plaintiffs' steering committee working groups for discovery coordination. She brings a rare combination of biochemistry training and trial experience to NEC cases, enabling her to cross-examine corporate scientists and present medical evidence with clarity and authority. She has represented more than 150 NEC families and is known for her compassionate approach to working with parents navigating profound grief while pursuing justice.
Education
- J.D., Northwestern Pritzker School of Law (2006)
- B.S., Biochemistry, University of Illinois Urbana-Champaign (2003)
Robert Denton
Partner — Product Liability
Houston, TX
Robert Denton has built one of Texas's most active NEC formula litigation practices over the past six years, representing families across Harris, Dallas, Bexar, and Travis counties whose premature infants were harmed by Enfamil Premature and Similac Special Care formula. His product liability background — initially developed in pharmaceutical and medical device cases — translated naturally to NEC litigation when the scientific evidence against Abbott and Mead Johnson became impossible to ignore. Robert has tried four NEC cases to verdict in Texas state courts and achieved several confidential settlements in the eight-figure range. He is a frequent speaker at Texas Trial Lawyers Association seminars on NEC science and the MDL bellwether process.
Education
- J.D., University of Texas School of Law (2009)
- B.A., Biology, Rice University (2006)
Denise Okafor
Senior Associate — Wrongful Death & Catastrophic Injury
Miami, FL
Denise Okafor brings a uniquely powerful combination of nursing training and trial experience to NEC baby formula cases. Before law school, she worked as a NICU nurse for three years — an experience that shaped her understanding of the vulnerabilities of premature infants and the critical role that formula feeding decisions play in NICU care. That clinical foundation allows her to speak the language of neonatologists, parse NICU feeding logs with expert precision, and communicate the human reality of NEC to juries with authenticity and compassion. Based in Miami, Denise represents NEC families throughout Florida and the Southeast and has recovered over $25 million for families in wrongful death and catastrophic injury cases involving premature infant harm.
Education
- J.D., University of Florida Levin College of Law (2011)
- B.S., Nursing (BSN), Florida A&M University (2007)
Frequently Asked Questions
NEC Baby Formula Lawsuit Filing Deadlines
The statute of limitations for NEC baby formula claims is one of the most nuanced areas of mass tort law because most victims are premature infants — either children who survived with injuries or babies who did not survive. Understanding how minor tolling and discovery rules apply is critical for families who may still have valid claims even if the NEC diagnosis occurred years ago.
Tolling for Minor Children and the Discovery Rule
In most states, the statute of limitations for personal injury claims belonging to a minor child is tolled — meaning paused — until the child reaches the age of majority (18 years old). This is one of the most important procedural protections for NEC families. It means that a child born premature in 2018 who was diagnosed with NEC and survived with short bowel syndrome or neurodevelopmental disabilities generally has until age 20 (two years after turning 18) or longer to bring their own personal injury claim in most states, even if their parents never filed a lawsuit. Parents who bring claims on behalf of their minor children (as next friend or guardian) are typically subject to the standard adult SOL from the date of diagnosis or the date they knew or should have known of the potential legal claim — whichever is later. The discovery rule provides additional time when the connection between the formula and NEC was not reasonably discoverable: for many families, the link between NICU formula feeding and NEC was not known until receiving legal information or news coverage about the MDL, which courts in some jurisdictions have treated as the trigger for the SOL clock. For wrongful death claims (infants who died from NEC), the SOL runs from the date of death and applies to the parents or estate — minor tolling does not apply because there is no surviving minor plaintiff. In most states wrongful death SOL is 2-3 years from date of death. However, the discovery rule may toll even wrongful death claims if the causal link to formula was not reasonably ascertainable at the time of death. Contact an attorney immediately regardless of when the NEC diagnosis or death occurred — do not assume your claim is time-barred before speaking with counsel.
Real-World Examples
A premature baby is born in Texas in 2021, fed Similac Special Care in the NICU, diagnosed with Stage III NEC, and undergoes emergency bowel resection. She survives but has short bowel syndrome. Her parents never filed a lawsuit.
Texas has a 2-year personal injury SOL (Tex. Civ. Prac. & Rem. Code § 16.003) but tolls it for minors until age 18. The child's personal injury claim does not expire until 2041 (age 20). Parents filing on the child's behalf as next friend are subject to the adult SOL — Texas also has a discovery rule, and many courts have found the SOL runs from when parents knew or should have known of the formula-NEC connection, not necessarily from the NEC diagnosis date. Parents should consult counsel immediately.
A premature infant dies from NEC in Illinois in 2022 after being fed Enfamil Premature in a Chicago-area NICU. The parents did not know about the formula-NEC link until reading about the MDL in 2025.
Illinois has a 2-year wrongful death SOL (735 ILCS 5/13-202). The parents filed a suit in 2025, which is more than 2 years after the death. However, Illinois recognizes the discovery rule for wrongful death claims. If a court finds that the parents could not reasonably have known of the causal link between formula and NEC until 2025, the SOL may be tolled. This is a contested legal question requiring immediate attorney consultation. The Northern District of Illinois MDL has addressed SOL issues in the context of case-specific facts.
Bottom Line
Do not assume your NEC claim is time-barred without speaking to an attorney. Minor tolling protects the claims of surviving NEC children in most states until age 18 (plus the standard SOL period). Discovery rule arguments can extend deadlines for parents who only recently learned of the formula-NEC connection. Wrongful death claims are more time-sensitive — contact an attorney immediately if your baby died from NEC.
In-Depth Guides
NEC Disease Overview: Stages, Symptoms, and What Happens in the NICU
Necrotizing Enterocolitis is a staged disease. Early detection (Stage I) allows medical management; advanced NEC (Stage III) requires emergency bowel surgery with a mortality rate of 20-30%. Understanding the stages, warning signs, and typical NICU progression is essential for families trying to understand what happened to their baby and whether they have a legal claim.
Read guideNEC Evidence and Records: What to Gather and Why It Matters
Building a successful NEC formula case requires three categories of records: (1) NICU feeding logs documenting formula product and volume; (2) diagnostic records confirming the NEC diagnosis; and (3) long-term medical records documenting the lasting harm. You do not need these records before contacting an attorney — your attorney can obtain them for you — but understanding what is needed helps families gather and preserve evidence.
Read guideNEC Statute of Limitations: State-by-State Deadlines and Minor Tolling Rules
The statute of limitations for NEC formula cases is among the most nuanced in all of mass tort law. Most states toll the SOL for personal injury claims belonging to minor children until the child turns 18 — meaning surviving NEC children often have claims that will not expire for many years. Parents filing their own claims (wrongful death or loss of consortium) face shorter deadlines. Do not assume your claim is time-barred without consulting a NEC attorney.
Read guideNEC Formula Settlements and Verdicts: What Cases Have Resolved and For How Much
NEC formula cases have produced some of the most significant verdicts in the history of mass tort litigation, with individual jury awards ranging from $1.5 million to $495 million. MDL bellwether trials are actively shaping settlement values in 2025-2026. Understanding the landscape of resolved cases helps families calibrate the potential value of their own claims.
Read guideSimilac NEC Lawsuit: Abbott Laboratories and Similac Special Care Formula
Abbott Laboratories manufactures Similac Special Care — the most widely used cow's milk-based premature infant formula in the United States. Abbott has faced thousands of NEC lawsuits across state and federal courts, with bellwether verdicts in MDL 3026 producing nine-figure jury awards. Families whose premature infants developed NEC after receiving Similac in the NICU may have viable product liability claims against Abbott.
Read guideEnfamil NEC Lawsuit: Mead Johnson/Reckitt and Enfamil Premature Formula
Mead Johnson Nutrition — now owned by the British consumer goods giant Reckitt — manufactures Enfamil Premature, a cow's milk-based premature infant formula widely used in NICUs. Mead Johnson has faced some of the largest NEC jury verdicts in history, including a $495 million verdict in Missouri and a $60 million verdict in Illinois. Families whose premature infants received Enfamil in the NICU should contact a NEC attorney immediately.
Read guideWhy Premature Infants Are Uniquely Vulnerable to NEC
The extreme vulnerability of premature infants to NEC is not an unfortunate coincidence — it is a biological certainty rooted in the profound immaturity of the preterm gut. Understanding why preterm infants are uniquely at risk helps families understand both the medical reality of what happened to their baby and why the NEC risk associated with cow's milk formula should have been disclosed more clearly.
Read guideBreast Milk vs. Formula and NEC: AAP Guidelines and the Donor Milk Alternative
The American Academy of Pediatrics, the World Health Organization, and the Human Milk Banking Association of North America all recommend pasteurized donor breast milk — not cow's milk-based formula — as the preferred alternative when a mother's own milk is unavailable for premature infants. The failure of Abbott and Mead Johnson to acknowledge this guidance in their marketing to NICUs is central to the NEC litigation.
Read guideNEC MDL 3026 in the Northern District of Illinois: What Families Need to Know
MDL No. 3026 — In Re: Abbott Laboratories, et al., Preterm Infant Formula Products Liability Litigation — is pending before Chief Judge Rebecca R. Pallmeyer in the United States District Court for the Northern District of Illinois. Understanding how the MDL works, what the bellwether trial program has produced, and how your individual case fits into the larger litigation is essential for families considering filing a NEC formula claim.
Read guideNEC Wrongful Death Claims: When a Premature Baby Does Not Survive
Losing a premature baby to NEC is an unimaginable tragedy. Families who lost their infants after NEC developed following formula feeding in the NICU may have wrongful death claims against Abbott and Mead Johnson. These cases carry some of the highest verdicts in the NEC litigation — including nine-figure jury awards — because juries respond powerfully to the preventable death of a premature baby.
Read guideNEC Long-Term Disabilities: Short Bowel Syndrome, TPN, and Neurodevelopmental Harm
Surviving NEC is only the beginning of a long medical journey for many premature infants. Short Bowel Syndrome, TPN dependency, intestinal failure-associated liver disease, and neurodevelopmental disabilities including cerebral palsy and cognitive impairment are common long-term sequelae of NEC. These lifelong medical needs dramatically increase the damages available in surviving-infant NEC claims.
Read guideNEC Hospital Liability: Can the NICU or Hospital Also Be Held Responsible?
In addition to product liability claims against Abbott and Mead Johnson, some NEC families may have medical malpractice claims against the hospital or NICU if the medical team deviated from the standard of care by failing to follow evidence-based breast milk guidelines, failing to inform parents of the NEC risk of formula, or failing to timely diagnose and treat NEC once it developed.
Read guideState-Specific Information
Sources & References
- Lucas A, Cole TJ. Breast milk and neonatal necrotising enterocolitis. The Lancet. 1990;336(8730):1519-1523. — The Lancet
- McGuire W, Anthony MY. Donor human milk versus formula for preventing necrotising enterocolitis in preterm infants: systematic review. Archives of Disease in Childhood. 2003;87(3):F167-F172. — Archives of Disease in Childhood
- Quigley M, Embleton ND, McGuire W. Formula versus donor breast milk for feeding preterm or low birth weight infants. Cochrane Database of Systematic Reviews. 2019;(7):CD002971. — Cochrane Database of Systematic Reviews
- Sullivan S, et al. An exclusively human milk-based diet is associated with a lower rate of necrotizing enterocolitis than a diet of human milk and bovine milk-based products. Journal of Pediatrics. 2010;156(4):562-567. — Journal of Pediatrics
- Corpeleijn WE, et al. Donor human milk in the neonatal intensive care unit: policy, pragmatics and progress. Nutrients. 2012;4(8):1022-1029. — Nutrients
- In Re: Abbott Laboratories, et al., Preterm Infant Formula Products Liability Litigation, MDL No. 3026 (N.D. Ill.). — United States District Court, Northern District of Illinois